CASI PHARMACEUTICALS INC's ticker is CASI and the CUSIP is 14757U109. A total of 60 filers reported holding CASI PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,089,000 | +1.2% | 1,345 | 0.0% | 0.00% | – |
| Q4 2021 | $1,076,000 | -51.3% | 1,345 | -27.6% | 0.00% | – |
| Q3 2021 | $2,210,000 | -23.2% | 1,857 | 0.0% | 0.00% | – |
| Q2 2021 | $2,878,000 | -85.5% | 1,857 | -77.6% | 0.00% | – |
| Q1 2021 | $19,870,000 | -39.3% | 8,279 | -25.4% | 0.00% | – |
| Q4 2020 | $32,721,000 | +43.1% | 11,092 | -25.8% | 0.00% | – |
| Q3 2020 | $22,863,000 | +115.4% | 14,943 | +252.0% | 0.00% | – |
| Q2 2020 | $10,612,000 | -66.4% | 4,245 | -72.6% | 0.00% | – |
| Q1 2020 | $31,565,000 | +39.3% | 15,473 | +111.1% | 0.00% | – |
| Q4 2019 | $22,653,000 | -15.2% | 7,331 | -8.3% | 0.00% | – |
| Q3 2019 | $26,713,000 | +42.7% | 7,998 | +36.7% | 0.00% | – |
| Q2 2019 | $18,720,000 | -37.1% | 5,850 | -43.6% | 0.00% | – |
| Q1 2019 | $29,759,000 | +290.5% | 10,369 | +535.4% | 0.00% | – |
| Q3 2018 | $7,621,000 | -43.3% | 1,632 | -0.1% | 0.00% | – |
| Q2 2018 | $13,448,000 | – | 1,634 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IDG-Accel China Growth Fund III Associates L.P. | 7,973,536 | $19,934,000 | 16.36% |
| Wellington Shields & Co., LLC | 1,585,609 | $3,964,000 | 1.74% |
| Wellington Shields Capital Management, LLC | 1,321,745 | $3,304,000 | 0.53% |
| Ikarian Capital, LLC | 1,039,910 | $2,600,000 | 0.21% |
| Zebra Capital Management LLC | 50,658 | $127,000 | 0.18% |
| BOOTHBAY FUND MANAGEMENT, LLC | 139,183 | $348,000 | 0.02% |
| Manatuck Hill Partners, LLC | 15,090 | $38,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 205,200 | $513,000 | 0.01% |
| IHT Wealth Management, LLC | 26,000 | $65,000 | 0.01% |
| Vident Investment Advisory, LLC | 67,540 | $169,000 | 0.01% |